On Monday, Phathom Pharmaceuticals Inc (NASDAQ: PHAT) opened higher 9.18% from the last session, before settling in for the closing price of $4.25. Price fluctuations for PHAT have ranged from $2.21 to $19.71 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 42.60% at the time writing. With a float of $37.92 million, this company’s outstanding shares have now reached $69.64 million.
Let’s determine the extent of company efficiency that accounts for 427 employees. In terms of profitability, gross margin is 86.23%, operating margin of -349.84%, and the pretax margin is -307.2%.
Phathom Pharmaceuticals Inc (PHAT) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Phathom Pharmaceuticals Inc is 45.69%, while institutional ownership is 57.92%. The most recent insider transaction that took place on May 21 ’25, was worth 14,609. In this transaction Director of this company bought 3,780 shares at a rate of $3.86, taking the stock ownership to the 59,403 shares. Before that another transaction happened on May 14 ’25, when Company’s Director bought 6,300 for $3.32, making the entire transaction worth $20,919. This insider now owns 55,623 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 42.60% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Check out the current performance indicators for Phathom Pharmaceuticals Inc (PHAT). In the past quarter, the stock posted a quick ratio of 3.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.24, a number that is poised to hit -0.90 in the next quarter and is forecasted to reach -0.32 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Looking closely at Phathom Pharmaceuticals Inc (NASDAQ: PHAT), its last 5-days average volume was 0.96 million, which is a drop from its year-to-date volume of 1.4 million. As of the previous 9 days, the stock’s Stochastic %D was 82.08%. Additionally, its Average True Range was 0.44.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 43.63%, which indicates a significant decrease from 97.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 104.09% in the past 14 days, which was lower than the 124.74% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.35, while its 200-day Moving Average is $9.36. However, in the short run, Phathom Pharmaceuticals Inc’s stock first resistance to watch stands at $4.80. Second resistance stands at $4.97. The third major resistance level sits at $5.24. If the price goes on to break the first support level at $4.36, it is likely to go to the next support level at $4.09. Should the price break the second support level, the third support level stands at $3.92.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
There are currently 69,814K shares outstanding in the company with a market cap of 323.94 million. Presently, the company’s annual sales total 55,250 K according to its annual income of -334,330 K. Last quarter, the company’s sales amounted to 28,520 K and its income totaled -94,320 K.
